Lack of tissue oxygenation, also known as hypoxia, is involved in the development and progression of idiopathic pulmonary fibrosis (IPF), a study has found. The findings of the study, “Dysregulated expression of hypoxia-inducible factors augments myofibroblasts differentiation in idiopathic pulmonary fibrosis,” were published in the journal Respiratory Research.
NP-120, Algernon Pharmaceuticals‘ repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), surpassed two other globally approved therapies — Genentech‘s Esbriet (pirfenidone) and Boehringer Ingelheim‘s Ofev (nintedanib) — in reducing lung tissue scarring (fibrosis) in a mouse model of IPF. Current guidelines…
The Assistance Fund, an independent and charitable foundation, announced that it has launched a new copay assistance program to support people with idiopathic pulmonary fibrosis (IPF). Also known as TAF, the fund provides financial support to patients and families facing high medical out-of-pocket costs by partly covering co-payments, co-insurance,…
It wasn’t until Gordana Loleska’s son David was 14 years old that doctors in their native North Macedonia diagnosed his kidney, vision, and hearing problems as Alport syndrome. Although she had known for years that something was wrong, the news that David would battle a lifelong rare disease devastated…
A signaling molecule called interleukin-25 (IL-25) was found to support lung fibroblast proliferation and promote lung inflammation and fibrosis in mice, a study shows. The findings suggest that blocking IL-25 may prevent many of the hallmark features of idiopathic pulmonary fibrosis (IPF), representing a new therapeutic target for this…
A pulmonary rehabilitation program lowers the risk of mortality among patients with idiopathic pulmonary fibrosis after lung transplant, as well as reduces their need for ventilation support and the time they spend in the intensive care unit after the procedure, a new study reports. The findings of the study,…
Gli proteins can trigger fibroblast activation and support their role in promoting fibrosis in the lungs in response to damage to the airspaces, a study in mice shows. The study, “Gli signaling pathway modulates fibroblast activation and facilitates scar formation in pulmonary fibrosis,” was published in the journal…
Idiopathic pulmonary fibrosis (IPF) oral treatment candidate PLN-74809 can prevent the activation of the pro-fibrotic protein TGF-beta by up to 70% in healthy volunteers, according to final results of a Phase 1b trial. Being developed by Pliant Therapeutics, PLN-74809 is a small molecule and selective inhibitor of the…
A less toxic precursor formulation of the chemotherapeutic agent paclitaxel can reduce lung fibrosis in mice with pulmonary fibrosis, a study shows. The finding suggests that this compound, named baccatin III or BAC, has the potential to represent a new treatment strategy for…
A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…
Get regular updates to your inbox.
